The rest is Silence as Christély hands over to Sedgwick
This article was originally published in Scrip
Executive Summary
Thomas Christély, who was made CEO of Silence Therapeutics in September 2011 after rising through the executive ranks following his instrumental role in merging the company with Atugen (scripintelligence.com, 20 September 2011), has resigned for personal reasons and given up his place on the board. He will be succeeded by Dr Tony Sedgwick, who also joined Silence in September 2011 as chief business officer. Dr Sedgwick was previously CEO of Novacta Biosystems and chair of Plastid. Dr Georg Buchner, who was brought on board by Dr Sedgwick in October 2011, also from Novacta Biosystems, will take full responsibility for the business development team.